And it promotes blood vessel growth through pathways that don't fully overlap with BPC-157's, which is part of why the two peptides seem to work better together than apart [3]
Retrieved 2 May 2022, from Khavinson VKh, Bondarev IE, Butyugov AA
[42] [43] Even more surprising is the intracellular pathogen Chlamydia trachomatis , which lacks recognizable candidates for any genes involved in the biosynthesis or salvage of both NAD + and NADP + , and must acquire these coenzymes from its host
Retrieved 17 November 2025
"There are basically no published human efficacy trials for BPC-157." Phillips says all he can find is one small safety study from a decade ago, and a trial that only started enrolling participants this past February
(vi) signal transduction from the environment to cellular transcription machinery (Dickinson and Forman, 2002)